A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.

@article{Stinchcombe2013ARA,
  title={A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.},
  author={Thomas E. Stinchcombe and Joanna Roder and Amy H Peterman and Julia Grigorieva and Carrie B. Lee and Dominic T. Moore and Mark A. Socinski},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2013},
  volume={8 4},
  pages={
          443-51
        }
}
  • Thomas E. Stinchcombe, Joanna Roder, +4 authors Mark A. Socinski
  • Published in
    Journal of thoracic oncology…
    2013
  • Medicine
  • PURPOSE In a multicenter randomized phase II trial of gemcitabine (arm A), erlotinib (arm B), and gemcitabine and erlotinib (arm C), similar progression-free survival (PFS) and overall survival (OS) were observed in all arms. We performed an exploratory, blinded, retrospective analysis of plasma or serum samples collected as part of the trial to investigate the ability of VeriStrat (VS) to predict treatment outcomes. METHODS Ninety-eight patients were assessable, and the majority had stage IV… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 28 CITATIONS